OncoMatch/Clinical Trials/NCT04217512
Pantoprazole in Cisplatin Nephrotoxicity
Is NCT04217512 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Pantoprazole low dose and Pantoprazole high dose for oncology.
Treatment: Pantoprazole low dose · Pantoprazole high dose · Cisplatin — Pantoprazole in Cisplatin Nephrotoxicity
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
GFR less than 59 [excluded]
Liver function
Elevated liver enzymes more than 3 fold [excluded]
GFR less than 59. Elevated liver enzymes more than 3 fold.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify